Experiences with
Chronic leukaemia5,591 public posts
Want to take advantage of all our features? Just log in!
or
STATIC now beginning to open at sites in the UK
The long awaited successor to FLAIR for patients randomised to one of the Ibrutinib arms is finally ready to open at sites in the UK.
When each site is ready will be up to local researchers and resource availability but the trial will be conducted in 100 NHS Centres in the UK (England, Wales, Scotland
Concise summary of the treatment history of CLL from the 1950s to the present, by Dr Bruce Cheson, contributor to the iwCLL and much more
I knew Chlorambucil use for CLL dated back to the 1950's but I hadn't appreciated that was also the case for cyclophosphamide, (the 'C' in FCR). It took until the early 90's before Fludarabine, the 'F' in FCR joined, then Rituximab (the 'R') just over 20 years ago, started the long reign of FCR as the
Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
[i]The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA (NCT03336333), in patients with previously untreated CLL, and ALPINE (NCT03734016), in patients with R/R CLL. In these two trials, BRUKINSA demonstrated superior efficacy versus either bendamustine plus rituximab